Analysis of the implementation of the federal assurance program of supporting beneficiaries with indispensable medicinal preparations in the subjects of the Russian Federation

Cover Page

Cite item

Full Text

Abstract

The aim of the research was to study the main indicative indicators of the implementation of the federal program “Provision of Essential Medicines” in 20 constituent entities of the Russian Federation based on the results of 2018 and 2019.

Materials and methods. The analyzed data were provided on the basis of the request cards specially designed by the health authorities of 20 subjects of the Russian Federation located in seven federal districts.

Results. It has been established that the funds allocated to the constituent entities of the Russian Federation, directly depend on the number of beneficiaries who retained the right to receive state social assistance in the form of a set of social services. These funds also correlate with the indicator “Population of the subject of the Russian Federation”. In all the studied constituent entities of the Russian Federation, more than 50% of the total number of people who retained the right to preferential drug provision in 2018–2019, asked for medical help as part of the program “Provision of Essential Medicines”. Herein, in the constituent entities of the Russian Federation, the average cost of one prescription amounted to 1,107.2 rubles in 2018 and 1,297.2 rubles in 2019. The estimated indicator “The average actual expenditures per 1 citizen entitled to state social assistance in the form of a set of social services, amounted to 1,723.0±90.2 rubles in 2018 and 1,526.8±80.5 rubles in 2019, which is higher than the approved input normative (823.3 rubles and 861.8 rubles in 2018 and 2019, respectively).

Conclusion. Thus, an excess of average actual expenditures per citizen entitled to state social assistance in the form of a set of social services, was notified over the standards established by the decrees of the Government of the Russian Federation. The revealed discrepancy between the normative and actual expenditures can also be an indirect confirmation of the fact that the most needy beneficiaries with chronic diseases remained in the program “Provision of Essential Medicines”.

About the authors

Irina K. Petrukhina

Samara State Medical University

Author for correspondence.
Email: ikpetrukhina@samsmu.ru
ORCID iD: 0000-0001-6207-5575

Doctor of Sciences (Pharmacy), Associate Professor, the Dean of the Faculty of Pharmacy, the Head of the Department of Management and Economics of Pharmacy

Russian Federation, 89, Chapaevskaya St., Samara, 443099

R. I. Yagudina

First Moscow State Medical University n. a. I.M. Sechenov

Email: yagudina@inbox.ru
ORCID iD: 0000-0002-9080-332X

Doctor of Sciences (Pharmacy), Professor, the Head of the Department of Pharmaceutical Provision and Pharmacoeconomics

Russian Federation, 8/2, Trubetskaya St., Moscow, 119991

Tatyana K. Ryazanova

Samara State Medical University

Email: t.k.ryazanova@samsmu.ru
ORCID iD: 0000-0002-4581-8610

Candidate of Sciences (Pharmacy), Senior Lecturer, the Department of Management and Economics of Pharmacy

Russian Federation, 89, Chapaevskaya St., Samara, 443099

Vladimir A. Kurkin

Samara State Medical University

Email: v.a.kurkin@samsmu.ru
ORCID iD: 0000-0002-7513-9352

Doctor of Sciences (Pharmacy), Professor, the Head of the Department of Pharmacognosy with Botany and Fundamentals of Phytotherapy

Russian Federation, 89, Chapaevskaya St., Samara, 443099

Sergey V. Pervushkin

Samara State Medical University

Email: s.v.pervushkin@samsmu.ru
ORCID iD: 0000-0002-7000-271X

Doctor of Sciences (Pharmacy), Professor, the Head of the Department of Pharmaceutical Technology with a course in biotechnology

Russian Federation, 89, Chapaevskaya St., Samara, 443099

Anna V. Egorova

Samara State Medical University

Email: a.v.egorova@samsmu.ru

Candidate of Sciences (Pharmacy), Assistant of the Department of Management and Economics of Pharmacy

Russian Federation, 89, Chapaevskaya St., Samara, 443099

Larisa V. Loginova

Samara State Medical University

Email: l.v.loginova@samsmu.ru

Assistant of the Department of Management and Economics of Pharmacy

Russian Federation, 89, Chapaevskaya St., Samara, 443099

Aliya I. Khusainova

Samara State Medical University

Email: a.i.khusainova@samsmu.ru
ORCID iD: 0000-0002-3924-8914

Candidate of Sciences (Pharmacy), Senior Lecturer, the Department of Management and Economics of Pharmacy

Russian Federation, 89, Chapaevskaya St., Samara, 443099

Polina R. Blinkova

Samara State Medical University

Email: p.r.blinkova@samsmu.ru

post-graduate student, the Department of Management and Economics of Pharmacy

Russian Federation, 89, Chapaevskaya St., Samara, 443099

References

  1. Alexandrova OY. Implementing the program for essential pharmaceutical provision (ONLP) – challenges faced by regions. Remedium. 2015. №12. С. 62–65. doi: 10.21518/1561-5936-2015-12-62-65. Russian.
  2. Telnova EA. EXTENSIVE DRUG COVERAGE – ONLS PROGRAM IS 10 YEARS. Vestnik Roszdravnadzora 2016;5:143-147. doi: 10.35576/2070-7940-2019-2019-6-74-81. Russian.
  3. Petrukhina IK, Yagudina RI, Egorova AV, Ryazanova TK. Implementation of the federal drug assistance program in the Privolzhsky Federal District, analysis of indicators. Aspirantskiy Vestnik Povolzhiya. 2018;(1-2):25–32. doi: 10.17816/2075-2354.2018.18.25-32. Russian.
  4. Kovaleva KA, Narkevich IA, Nemyatyh OD, Vasyagina YUA. Analiz federal’nyh programm l’gotnogo lekarstvennogo obespecheniya naseleniya // Remedium. ZHurnal o rossijskom rynke lekarstv i medicinskoj tekhniki. 2019;3:54–58. doi: 10.21518/1561-5936-2019-3-54-58. Russian.
  5. Telnova EA, Proklova TN. THE PROGRAM CONTINUES TO WORK, AND THE PROBLEMS REMAIN. Byulleten’ nacional’nogo nauchno-issledovatel’skogo instituta obshchestvennogo zdorov’ya imeni NA Semashko. 2019;2:99–112. doi: 10.25742/nriph.2019.02.013. Russian.
  6. Grosheva M. V Rossii poyavitsya federal’nyj registr pacientov-l’gotnikov. [Internet]. Farmacevticheskij vestnik. 2020.Available from: URL: https://pharmvestnik.ru/content/news/V-Rossii-poyavitsya-federalnyi-registr-pacientov-lgotnikov.html. [cited 2020 May 28]. Russian.
  7. Tsomartova FV. State guarantees of availability of drugs in russia and abroad. Journal of Foreign Legislation and Comparative Law. 2018;4(71):161–170. doi: 10.12737/art.2018.4.21. Russian.
  8. Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, Kösters JP, Vernby A. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD007017. doi: 10.1002/14651858.CD007017.
  9. Hermanowski TR, Drozdowska AK, Kowalczyk M. Institutional framework for integrated Pharmaceutical Benefits Management: results from a systematic review. International Journal of Integrated Care. 2015;15(3):e036. doi: 10.5334/ijic.2253.
  10. Drugs and Money Prices, affordability and cost containment. Edited by M.N.G. Dukes, Norway F.M. Haaijer-Ruskamp, C.P. de Joncheere, A.H. Rietveld. International Journal of Risk & Safety in Medicine. 2002;15:1–3.
  11. U.S. Pharmacy Benefit Management Market Size, Share & Trends Analysis Report By Business Model (Standalone, Health Insurance Providers, Retail Pharmacy), By End Use (Commercial, Federal), And Segment Forecasts, 2019–2026. Published Date: Mar, 2019. Report ID: GVR-2-68038-826-8. 100 p. [cited: 2020 May 13]. Available from: https://www.grandviewresearch.com/industry-analysis/us-pharmacy-benefit-management-pbm-market .
  12. Aityan TV. Comparison of drug supply systems in europe and usa. Lessons for Russia / Regional Economics: Theory and Practice. 2018;16(4):624–639. doi: 10.24891/re.16.4.624. Russian.
  13. Vlasov VV, Plavinskij SL. Varianty lekarstvennogo obespecheniya dlya Rossii: uroki stran Evropy i vsego mira. Obshchestvo specialistov dokazatel’noj mediciny. Moscow.2012. [cited: 2020 May 13]. Available from: http://osdm.org/wp-content/uploads/2012/09/Report120919clear.pdf. Russian.
  14. Lukyantseva DV, Mel’nikova LS, Tatarinov AP. The international practice of drug supply in the outpatient segment. Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(4):44–52. doi: 10.17749/2070-4909.2017.10.4.044-052. Russian.
  15. Health systems: the time of change. Review summary.European Observatory on Health Systems and Policies. Canada. 2012. [cited: 2020 May 13]. Available from: http://www.euro.who.int/_data/assets/pdf_file/0010/184672/Summary-HiT-Canada-2013-Rus.pdf?ua=1.
  16. Boyle S. United Kingdom (England): Health system review. Health Syst Transit. 2011;13(1):1–483.
  17. Appleby J, Devlin N, Parkin D. NICE’s cost effectiveness threshold. BMJ. 2007;335(7616):358–9. doi: 10.1136/bmj.39308.560069.BE.
  18. Mossialos E, Srivastava D. Pharmaceutical policies in Finland. Challenges and opportunitiesю – World health organization. 2009:141 p.
  19. Dolya vozmeshcheniya raskhodov na lekarstvennye sredstva v Kitae dostignet 50%ю Novosti GMP. 2019 March 15. [cited: 2020 April 13]. Available from: https://gmpnews.ru/2019/03/dolya-vozmeshhaemyx-rasxodov-na-lekarstva-v-kitae-dostignet-50/. Russian.
  20. World Health Report: HEALTH SYSTEMS FINANCING: The path to universal coverage. WHO. 2010. [cited: 2017 October 25]. Available from: http://www.who.int/whr/2010/whr10_ru.pdf?ua=1. Russian.
  21. Trivedi AN, Moloo H, Mor V. Increased ambulatory care copayments and hospitalizations among the elderly. The New England journal of medicine. 2010;362(4):320–328. doi: 10.1056/NEJMsa0904533.
  22. Calabrese D. Comparing pharmacy benefit managers: moving well beyond the simple spreadsheet analysis. Am Health Drug Benefits. 2008;1(5):9–19.
  23. Shapovalov VV Jr, Shapovalov VV, Shapovalovа VA, Rohozhnikova O.V. Comparative analysis of the pharmaceutical care in the Russian Federation, Ukraine and Belarus in providing for privileged categories of population. Nauchnye vedomosti BelGU. Seriya: Medicina. Farmaciya. 2015;10 (207):226238. Russian.
  24. ZHulev YU. Preparaty dolzhny byt’ dostupny dlya vsekh. Rossijskaya gazeta. 2019;120(7878). [cited: 2020 April 28]. Available from: https://rg.ru/2019/06/04/sistema-lgotnogo-obespecheniia-lekarstvami-ustarela.html.
  25. Telnova EA. Experiment ahead of time: about the Moscow experiment on preferential drug provision. Remedium. 2019;10. doi: 10.21518/1561-5936-2019-9-16-25.

Copyright (c) 2020 Petrukhina I.K., Yagudina R.I., Ryazanova T.K., Kurkin V.A., Pervushkin S.V., Egorova A.V., Loginova L.V., Khusainova A.I., Blinkova P.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies